Health Minister Jo Etienne Abela announced a €6 million investment that will extend access to the medication Entresto (sacubitril/valsartan) through the Government formulary, benefiting 4,000 people.The measure forms part of ongoing efforts to improve care for patients living with heart failure.This chronic condition affects thousands of individuals and has a significant impact on quality of life. Recent medical advances have enabled more effective treatments that reduce the risk of hospitalisation and improve symptoms.Entresto is a modern therapy already used successfully in several countries, particularly for patients who do not respond adequately to standard treatments.The medication can be used by adults, adolescents and children aged one year and over who suffer from chronic heart failure. It is available in three different dosages to better match individual patient needs.Abela said the initiative builds on other steps already taken, including the introduction of medications such as empagliflozin (Jardiance), and forms part of a broader vision that places patients at the centre of healthcare, with a focus on evidence-based treatment.He explained that the investment reflects a commitment to modern and sustainable care. Implementation is expected to begin gradually in the coming days, with monitoring in place to ensure continuity of care.The rollout will follow a structured process in line with the National Formulary, including clear eligibility criteria and prescribing protocols to ensure safe and equitable use. The procurement process is in its final stages.“This measure helps safeguard patients with heart conditions and continues to strengthen a healthcare system that offers quality, equity and hope to all patients. The Government remains committed to providing the best possible care to patients in Malta and Gozo while safeguarding the sustainability of our systems,” Minister Abela said.Share this with your household•